U.S. Antiarrhythmic Drugs Market Size & Outlook, 2025-2030
Related Markets
U.S. antiarrhythmic drugs market highlights
- The U.S. antiarrhythmic drugs market generated a revenue of USD 369.7 million in 2024 and is expected to reach USD 512.9 million by 2030.
- The U.S. market is expected to grow at a CAGR of 5.6% from 2025 to 2030.
- In terms of segment, beta blockers was the largest revenue generating drug class in 2024.
- Potassium Channel Blockers is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antiarrhythmic drugs market data book summary
| Market revenue in 2024 | USD 369.7 million |
| Market revenue in 2030 | USD 512.9 million |
| Growth rate | 5.6% (CAGR from 2025 to 2030) |
| Largest segment | Beta blockers |
| Fastest growing segment | Potassium Channel Blockers |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Potassium Channel Blockers, Sodium Channel Blockers, Beta Blockers, Calcium Channel Blockers, Other Drug Class |
| Key market players worldwide | Pfizer Inc, Novartis AG ADR, Viatris Inc, Baxter International Inc, Sanofi SA, GlaxoSmithKline Consumer Healthcare (GSK CH India), Mayne Pharma Group Ltd, Bora Pharmaceuticals, Merck KGaA |
Other key industry trends
- In terms of revenue, U.S. accounted for 33.3% of the global antiarrhythmic drugs market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. antiarrhythmic drugs market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 31.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antiarrhythmic Drugs Market Scope
Antiarrhythmic Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Mayne Pharma Group Ltd | View profile | 160 | 1538 Main North Road, Salisbury South, Salisbury, SA, Australia, 5106 | http://www.maynepharma.com |
| Bora Pharmaceuticals | View profile | 501-1000 | Taipei, T'ai-pei, Taiwan, Asia | http://www.bora-corp.com/ |
| GlaxoSmithKline Consumer Healthcare (GSK CH India) | View profile | 1001-5000 | Gurgaon, Haryana, India, Asia | https://india-consumer.gsk.com/ |
| Viatris Inc | View profile | 38000 | 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 | https://www.viatris.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
| Baxter International Inc | View profile | 60000 | One Baxter Parkway, Deerfield, IL, United States, 60015 | https://www.baxter.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
U.S. antiarrhythmic drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antiarrhythmic drugs market will help companies and investors design strategic landscapes.
Beta blockers was the largest segment with a revenue share of 36.87% in 2024. Horizon Databook has segmented the U.S. antiarrhythmic drugs market based on potassium channel blockers, sodium channel blockers, beta blockers, calcium channel blockers, other drug class covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to U.S. antiarrhythmic drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. antiarrhythmic drugs market databook
-
Our clientele includes a mix of antiarrhythmic drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. antiarrhythmic drugs market , including forecasts for subscribers. This country databook contains high-level insights into U.S. antiarrhythmic drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
US Sodium Channel Blockers - Antiarrhythmic Drugs Market, 2024 - 2030 (US$M)
U.S. Antiarrhythmic Drugs Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
